Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy | Zendy

Marianna Sabatino | Zendy; Seunghee KimSchulze | Zendy; Monica C. Panelli | Zendy; David F. Stroncek | Zendy; Ena Wang | Zendy; Bret Taback | Zendy; Dae Won Kim | Zendy; Gail DeRaffele | Zendy; Zoltán Pós | Zendy; Francesco M. Marincola | Zendy; Howard L. Kaufman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

Author(s) -

Marianna Sabatino,

Seunghee KimSchulze,

Monica C. Panelli,

David F. Stroncek,

Ena Wang,

Bret Taback,

Dae Won Kim,

Gail DeRaffele,

Zoltán Pós,

Francesco M. Marincola,

Howard L. Kaufman

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.19.1106

Subject(s) - medicine , oncology , vascular endothelial growth factor , multivariate analysis , interleukin , immunology , cytokine , vegf receptors

High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore